Does a higher omega-6 to omega-3 ratio favor allergic inflammation?

Dietary and tissue ratios of polyunsaturated fatty acids play a critical role in modulating systemic and localized inflammatory pathways.

Mechanistic pathways

• Enzymatic competition: Arachidonic acid (AA, an omega-6) and eicosapentaenoic acid (EPA, an omega-3) compete directly for cell membrane integration and metabolic processing.
• The 5-LOX pathway: When the tissue AA/EPA ratio is elevated, the enzyme 5-lipoxygenase (5-LOX) preferentially metabolizes free AA into highly active, pro-inflammatory mediators, primarily leukotriene B4 (LTB4).
• Potency differences: Conversely, higher levels of EPA shift 5-LOX metabolism toward the synthesis of leukotriene B5 (LTB5), which is 10 to 100 times less potent than LTB4 in promoting leukocyte chemotaxis and cellular inflammatory activation.

Clinical implications for allergic inflammation

• Allergic pathology: High levels of AA-derived leukotrienes act as powerful drivers of allergic responses, inducing bronchoconstriction, promoting eosinophil and neutrophil tissue infiltration, and sustaining airway inflammation in respiratory conditions.
• Therapeutic modulation: Clinical and ex vivo studies demonstrate that lowering the AA/EPA ratio through targeted omega-3 supplementation significantly curtails the synthesis of these highly active leukotrienes, correlating with improved respiratory function and reduced severity of atopic symptoms.

Bottom line

• An elevated omega-6 to omega-3 (AA/EPA) ratio directly shifts cellular metabolism to favor the production of highly potent, arachidonic-acid-derived leukotrienes that actively amplify allergic inflammation, whereas increasing EPA competitively mitigates this pro-inflammatory cascade.